BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9. [PMID: 10189845 DOI: 10.1136/gut.43.2.203] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. [PMID: 15940615 DOI: 10.1053/j.gastro.2005.03.003] [Cited by in Crossref: 734] [Cited by in F6Publishing: 651] [Article Influence: 43.2] [Reference Citation Analysis]
2 Jin H, Guo J, Liu J, Lyu B, Foreman RD, Yin J, Shi Z, Chen JDZ. Anti-inflammatory effects and mechanisms of vagal nerve stimulation combined with electroacupuncture in a rodent model of TNBS-induced colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2017;313:G192-202. [DOI: 10.1152/ajpgi.00254.2016] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 12.8] [Reference Citation Analysis]
3 Jin H, Guo J, Liu J, Lyu B, Foreman RD, Shi Z, Yin J, Chen JDZ. Autonomically mediated anti-inflammatory effects of electrical stimulation at acupoints in a rodent model of colonic inflammation. Neurogastroenterol Motil 2019;31:e13615. [PMID: 31117153 DOI: 10.1111/nmo.13615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Weersma RK, van Dullemen HM, van der Steege G, Nolte IM, Kleibeuker JH, Dijkstra G. Review article: Inflammatory bowel disease and genetics. Aliment Pharmacol Ther. 2007;26 Suppl 2:57-65. [PMID: 18081650 DOI: 10.1111/j.1365-2036.2007.03476.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
5 Chandraiah SB, Ghosh S, Saha I, More SS, Annappa GS, Maiti AK. Substance P failed to reverse dextran sulfate sodium-induced murine colitis mediated by mitochondrial dysfunction: implications in ulcerative colitis. 3 Biotech 2021;11:199. [PMID: 33927989 DOI: 10.1007/s13205-021-02755-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Collins RA, Grounds MD. The Role of Tumor Necrosis Factor-alpha (TNF-α) in Skeletal Muscle Regeneration: Studies in TNF-α(-/-) and TNF-α(-/-)/LT-α(-/-) Mice. J Histochem Cytochem 2001;49:989-1001. [DOI: 10.1177/002215540104900807] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 17.8] [Reference Citation Analysis]
7 Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, Kirkland R, Deshpande AR, Singh S, Abreu MT. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2016;65:249-55. [PMID: 25670812 DOI: 10.1136/gutjnl-2014-308099] [Cited by in Crossref: 147] [Cited by in F6Publishing: 123] [Article Influence: 24.5] [Reference Citation Analysis]
8 Srivastava M, Zurakowski D, Cheifetz P, Leichtner A, Bousvaros A. Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:548-53. [PMID: 11740227 DOI: 10.1097/00005176-200111000-00007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
9 Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis. 2012;33:723-731. [PMID: 22235026 DOI: 10.1093/carcin/bgs006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 90] [Article Influence: 10.1] [Reference Citation Analysis]
10 Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med. 2012;52:2013-2037. [PMID: 22391222 DOI: 10.1016/j.freeradbiomed.2012.02.035] [Cited by in Crossref: 162] [Cited by in F6Publishing: 144] [Article Influence: 16.2] [Reference Citation Analysis]
11 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
12 El-Hodhod MA, Hamdy AM, Abbas AA, Moftah SG, Ramadan AA. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol 2012;12:44. [PMID: 22551310 DOI: 10.1186/1471-230X-12-44] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
13 Waetzig GH, Rosenstiel P, Arlt A, Till A, Bräutigam K, Schäfer H, Rose-John S, Seegert D, Schreiber S. Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J 2005;19:91-3. [PMID: 15514103 DOI: 10.1096/fj.04-2073fje] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 3.9] [Reference Citation Analysis]
14 Young LR, Borchers MT, Allen HL, Gibbons RS, McCormack FX. Lung-restricted macrophage activation in the pearl mouse model of Hermansky-Pudlak syndrome. J Immunol 2006;176:4361-8. [PMID: 16547274 DOI: 10.4049/jimmunol.176.7.4361] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
15 Barash J, Dushnitzki D, Barak Y, Miron S, Hahn T. Tumor necrosis factor (TNF)α and its soluble receptor (sTNFR) p75 during acute human parvovirus B19 infection in children. Immunology Letters 2003;88:109-12. [DOI: 10.1016/s0165-2478(03)00075-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett's carcinogenesis. Pathol Res Pract. 2012;208:269-280. [PMID: 22541897 DOI: 10.1016/j.prp.2012.03.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
17 Peng CC, Hsieh CL, Wang HE, Chung JY, Chen KC, Peng RY. Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease. Clin Nutr 2012;31:405-14. [PMID: 22154988 DOI: 10.1016/j.clnu.2011.11.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
18 McConnell BB, Yang VW. The Role of Inflammation in the Pathogenesis of Colorectal Cancer. Curr Colorectal Cancer Rep. 2009;5:69-74. [PMID: 19756239 DOI: 10.1007/s11888-009-0011-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
19 Hanawa T, Suzuki K, Kawauchi Y, Takamura M, Yoneyama H, Han GD, Kawachi H, Shimizu F, Asakura H, Miyazaki J, Maruyama H, Aoyagi Y. Attenuation of mouse acute colitis by naked hepatocyte growth factor gene transfer into the liver. J Gene Med 2006;8:623-35. [DOI: 10.1002/jgm.880] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
20 Wang J, Li D, Cang H, Guo B. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med 2019;8:4709-21. [PMID: 31222971 DOI: 10.1002/cam4.2327] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 20.7] [Reference Citation Analysis]
21 Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133. [PMID: 10338381 DOI: 10.1097/00054725-199905000-00008] [Cited by in Crossref: 267] [Cited by in F6Publishing: 246] [Article Influence: 11.6] [Reference Citation Analysis]
22 Toiyama Y, Araki T, Tanaka K, Mohri Y, Kusunoki M. Molecular Alterations in Inflammatory Colonic Carcinogenesis and Markers for Detecting Colitis-Associated Cancer. In: Kusunoki M, editor. Colitis-Associated Cancer. Tokyo: Springer Japan; 2016. pp. 85-105. [DOI: 10.1007/978-4-431-55522-3_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Burns R, Rivera-nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001;121:1428-36. [DOI: 10.1053/gast.2001.29568] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 7.3] [Reference Citation Analysis]
24 Ahmad T, Armuzzi A, Neville M, Bunce M, Ling KL, Welsh KI, Marshall SE, Jewell DP. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens. 2003;62:527-535. [PMID: 14617036 DOI: 10.1046/j.1399-0039.2003.00129.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
25 Fernandez-Botran R, Crespo FA, Sun X. Soluble cytokine receptors in biological therapy. Expert Opin Biol Ther 2002;2:585-605. [PMID: 12171504 DOI: 10.1517/14712598.2.6.585] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
26 Tahara T, Arisawa T. Potential usefulness of DNA methylation as a risk marker for digestive cancer associated with inflammation. Expert Rev Mol Diagn 2012;12:489-97. [PMID: 22702365 DOI: 10.1586/erm.12.38] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
27 Sami Ullah KR, Xiong YL, Miao YL, Ummair S, Dai W. Thalidomide and thalidomide analogues in treatment of patients with inflammatory bowel disease: Meta-analysis. World J Meta-Anal 2017; 5(5): 124-131 [DOI: 10.13105/wjma.v5.i5.124] [Reference Citation Analysis]
28 Zhu Z, Li M, Shu X, Bai A, Long S, Liu D, Lu N, Zhu X, Liao W. Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients. Clinics and Research in Hepatology and Gastroenterology 2017;41:210-6. [DOI: 10.1016/j.clinre.2016.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
29 Ba H, Jiang R, Zhang M, Yin B, Wang J, Li Z, Li B, Zhou X. Suppression of Transmembrane Tumor Necrosis Factor Alpha Processing by a Specific Antibody Protects Against Colitis-Associated Cancer. Front Immunol 2021;12:687874. [PMID: 34675913 DOI: 10.3389/fimmu.2021.687874] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157. [PMID: 11677207 DOI: 10.1053/gast.2001.28702] [Cited by in Crossref: 402] [Cited by in F6Publishing: 377] [Article Influence: 19.1] [Reference Citation Analysis]
31 Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol. 2004;18:577-596. [PMID: 15157829 DOI: 10.1016/j.bpg.2004.01.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
32 Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology. 2000;118:724-734. [PMID: 10734024 DOI: 10.1016/s0016-5085(00)70142-9] [Cited by in Crossref: 277] [Cited by in F6Publishing: 110] [Article Influence: 12.6] [Reference Citation Analysis]
33 De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, Signori E, Fazio VM. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog. 2011;10:9. [PMID: 21483655 DOI: 10.4103/1477-3163.78279] [Cited by in Crossref: 284] [Cited by in F6Publishing: 280] [Article Influence: 25.8] [Reference Citation Analysis]
34 Vorobjova T, Tagoma A, Oras A, Alnek K, Kisand K, Talja I, Uibo O, Uibo R. Celiac Disease in Children, Particularly with Accompanying Type 1 Diabetes, Is Characterized by Substantial Changes in the Blood Cytokine Balance, Which May Reflect Inflammatory Processes in the Small Intestinal Mucosa. J Immunol Res. 2019;2019:6179243. [PMID: 31214623 DOI: 10.1155/2019/6179243] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Inan MS, Tolmacheva V, Wang QS, Rosenberg DW, Giardina C. Transcription factor NF-kappaB participates in regulation of epithelial cell turnover in the colon. Am J Physiol Gastrointest Liver Physiol 2000;279:G1282-91. [PMID: 11093952 DOI: 10.1152/ajpgi.2000.279.6.G1282] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
36 O’neil D, Steidler L. Cytokines, Chemokines and Growth Factors in the Pathogenesis and Treatment of Inflammatory Bowel Disease. Cytokines and Chemokines in Autoimmune Disease. Boston: Springer US; 2003. pp. 252-85. [DOI: 10.1007/978-1-4615-0171-8_15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Ierna MX, Scales HE, Mueller C, Lawrence CE. Transmembrane tumor necrosis factor alpha is required for enteropathy and is sufficient to promote parasite expulsion in gastrointestinal helminth infection. Infect Immun 2009;77:3879-85. [PMID: 19564380 DOI: 10.1128/IAI.01461-08] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
38 Kozuch PL, Hanauer SB. General Principles and Pharmacology of Biologics in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2006;35:757-73. [DOI: 10.1016/j.gtc.2006.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
39 Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006;42:745-750. [PMID: 16517151 DOI: 10.1016/j.ejca.2006.01.012] [Cited by in Crossref: 269] [Cited by in F6Publishing: 249] [Article Influence: 16.8] [Reference Citation Analysis]
40 Yoo J, Nichols A, Song JC, Mammen J, Calvo I, Worrell RT, Cuppoletti J, Matlin K, Matthews JB. Bryostatin-1 attenuates TNF-induced epithelial barrier dysfunction: role of novel PKC isozymes. Am J Physiol Gastrointest Liver Physiol 2003;284:G703-12. [PMID: 12505880 DOI: 10.1152/ajpgi.00214.2002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
41 Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol 2001;16:763-9. [DOI: 10.1046/j.1440-1746.2001.02507.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
42 Mashukova A, Wald FA, Salas PJ. Tumor necrosis factor alpha and inflammation disrupt the polarity complex in intestinal epithelial cells by a posttranslational mechanism. Mol Cell Biol. 2011;31:756-765. [PMID: 21135124 DOI: 10.1128/mcb.00811-10] [Cited by in Crossref: 54] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
43 Dionne S, Laberge S, Deslandres C, Seidman EG. Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin Exp Immunol 2003;133:108-14. [PMID: 12823284 DOI: 10.1046/j.1365-2249.2003.02191.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
44 Wakita M, Edamatsu H, Li M, Emi A, Kitazawa S, Kataoka T. Phospholipase Cϵ Activates Nuclear Factor-κB Signaling by Causing Cytoplasmic Localization of Ribosomal S6 Kinase and Facilitating Its Phosphorylation of Inhibitor κB in Colon Epithelial Cells. J Biol Chem 2016;291:12586-600. [PMID: 27053111 DOI: 10.1074/jbc.M116.717561] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
45 Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A. Cellular and molecular pathways linking inflammation and cancer. Immunobiology. 2009;214:761-777. [PMID: 19616341 DOI: 10.1016/j.imbio.2009.06.014] [Cited by in Crossref: 174] [Cited by in F6Publishing: 156] [Article Influence: 13.4] [Reference Citation Analysis]
46 Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 2002;13:299-313. [PMID: 12220545 DOI: 10.1016/s1359-6101(02)00018-7] [Cited by in Crossref: 118] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
47 Ansary MM, Ishihara S, Oka A, Kusunoki R, Oshima N, Yuki T, Kawashima K, Maegawa H, Kashiwagi N, Kinoshita Y. Apoptotic cells ameliorate chronic intestinal inflammation by enhancing regulatory B-cell function. Inflamm Bowel Dis. 2014;20:2308-2320. [PMID: 25358066 DOI: 10.1097/mib.0000000000000240] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
48 Spoettl T, Hausmann M, Klebl F, Dirmeier A, Klump B, Hoffmann J, Herfarth H, Timmer A, Rogler G. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007;13:727-732. [PMID: 17260368 DOI: 10.1002/ibd.20107] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
49 Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther. 2007;25:419-427. [PMID: 17269997 DOI: 10.1111/j.1365-2036.2006.03211.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
50 Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol. 2003;3:642-655. [PMID: 12974479 DOI: 10.1038/nri1151] [Cited by in Crossref: 208] [Cited by in F6Publishing: 198] [Article Influence: 10.9] [Reference Citation Analysis]
51 Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40:723-751. [PMID: 11707060 DOI: 10.2165/00003088-200140100-00003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 86] [Article Influence: 4.8] [Reference Citation Analysis]
52 Coon C, Beagley KW, Bao S. The Role of Granulocyte Macrophage-Colony Stimulating Factor in Gastrointestinal Immunity to Salmonellosis. Scandinavian Journal of Immunology 2009;70:106-15. [DOI: 10.1111/j.1365-3083.2009.02279.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
53 Markey KA, Burman AC, Banovic T, Kuns RD, Raffelt NC, Rowe V, Olver SD, Don ALJ, Morris ES, Pettit AR, Wilson YA, Robb RJ, Randall LM, Korner H, Engwerda CR, Clouston AD, Macdonald KPA, Hill GR. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood 2010;115:122-32. [DOI: 10.1182/blood-2009-01-199927] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
54 Gayathri B, Manjula N, Vinaykumar K, Lakshmi B, Balakrishnan A. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases. International Immunopharmacology 2007;7:473-82. [DOI: 10.1016/j.intimp.2006.12.003] [Cited by in Crossref: 113] [Cited by in F6Publishing: 91] [Article Influence: 7.5] [Reference Citation Analysis]
55 Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Devière J, Franchimont D. Profile of soluble cytokine receptors in Crohn's disease. Gut 2005;54:488-95. [PMID: 15753533 DOI: 10.1136/gut.2004.043554] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
56 Zeissig S, Bergann T, Fromm A, Bojarski C, Heller F, Guenther U, Zeitz M, Fromm M, Schulzke JD. Altered ENaC expression leads to impaired sodium absorption in the noninflamed intestine in Crohn's disease. Gastroenterology. 2008;134:1436-1447. [PMID: 18355814 DOI: 10.1053/j.gastro.2008.02.030] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
57 Anandakumar P, Kamaraj S, Jagan S, Ramakrishnan G, Asokkumar S, Naveenkumar C, Raghunandhakumar S, Devaki T. Capsaicin inhibits benzo(a)pyrene-induced lung carcinogenesis in an in vivo mouse model. Inflamm Res 2012;61:1169-75. [DOI: 10.1007/s00011-012-0511-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
58 Biancheri P, Powell N, Monteleone G, Lord G, MacDonald TT. The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol 2013;34:564-71. [PMID: 24035478 DOI: 10.1016/j.it.2013.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
59 Hwang DY, Kim S, Hong HS. Substance-P Ameliorates Dextran Sodium Sulfate-Induced Intestinal Damage by Preserving Tissue Barrier Function. Tissue Eng Regen Med. 2017;15:63-73. [PMID: 30603535 DOI: 10.1007/s13770-017-0085-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
60 Kanneganti M, Mino-Kenudson M, Mizoguchi E. Animal models of colitis-associated carcinogenesis. J Biomed Biotechnol. 2011;2011:342637. [PMID: 21274454 DOI: 10.1155/2011/342637] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
61 Lee HJ, Lim HJ, Lee DY, Jung H, Kim M, Moon D, Kim KI, Lee M, Ryu J. Carabrol suppresses LPS-induced nitric oxide synthase expression by inactivation of p38 and JNK via inhibition of I-κBα degradation in RAW 264.7 cells. Biochemical and Biophysical Research Communications 2010;391:1400-4. [DOI: 10.1016/j.bbrc.2009.12.073] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
62 Parlesak A, Haller D, Brinz S, Baeuerlein A, Bode C. Modulation of Cytokine Release by Differentiated CACO-2 Cells in a Compartmentalized Coculture Model with Mononuclear Leucocytes and Nonpathogenic Bacteria. Scand J Immunol 2004;60:477-85. [DOI: 10.1111/j.0300-9475.2004.01495.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 3.6] [Reference Citation Analysis]
63 Dionne S, Ruemmele FM, Laberge S, Seidman EG. The effect of inflammation severity and of treatment on the production and release of TNFα by colonic explants in inflammatory bowel disease: COLONIC TNFα IN INFLAMMATORY BOWEL DISEASE. Alimentary Pharmacology & Therapeutics 2000;14:1435-42. [DOI: 10.1046/j.1365-2036.2000.00851.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
64 Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene. 2010;29:3313-3323. [PMID: 20400974 DOI: 10.1038/onc.2010.109] [Cited by in Crossref: 129] [Cited by in F6Publishing: 123] [Article Influence: 10.8] [Reference Citation Analysis]
65 Sekiguchi K, Koba R, Oka T, Tohya Y. Caliciviruses induce mRNA of tumor necrosis factor α via their protease activity. Virus Res 2021;306:198595. [PMID: 34637812 DOI: 10.1016/j.virusres.2021.198595] [Reference Citation Analysis]
66 Sugita N, Watanabe K, Kamata N, Yukawa T, Otani K, Hosomi S, Nagami Y, Tanaka F, Taira K, Yamagami H, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Kabata D, Shintani A, Arakawa T, Fujiwara Y. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease: Adalimumab with elemental diet in Crohn. Journal of Gastroenterology and Hepatology 2018;33:631-7. [DOI: 10.1111/jgh.13969] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
67 Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403. [PMID: 10940278 DOI: 10.1136/gut.47.3.397] [Cited by in Crossref: 826] [Cited by in F6Publishing: 754] [Article Influence: 37.5] [Reference Citation Analysis]
68 Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000;95:3452-3457. [PMID: 11151876 DOI: 10.1111/j.1572-0241.2000.03360.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 81] [Article Influence: 2.4] [Reference Citation Analysis]
69 Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Piqué JM, Panés J. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96. [PMID: 10861269 DOI: 10.1136/gut.47.1.88] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 4.5] [Reference Citation Analysis]
70 Rivkin A. Certolizumab pegol for the management of Crohn’s disease in adults. Clin Ther. 2009;31:1158-1176. [PMID: 19695385 DOI: 10.1016/j.clinthera.2009.06.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
71 Tak KH, Ahn E, Kim E. Increase in dietary protein content exacerbates colonic inflammation and tumorigenesis in azoxymethane-induced mouse colon carcinogenesis. Nutr Res Pract 2017;11:281-9. [PMID: 28765774 DOI: 10.4162/nrp.2017.11.4.281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
72 Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:200-210. [PMID: 17206679 DOI: 10.1002/ibd.20051] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
73 Ji Y, Dai Z, Sun S, Ma X, Yang Y, Tso P, Wu G, Wu Z. Hydroxyproline Attenuates Dextran Sulfate Sodium‐Induced Colitis in Mice: Involvment of the NF‐κB Signaling and Oxidative Stress. Mol Nutr Food Res 2018;62:1800494. [DOI: 10.1002/mnfr.201800494] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
74 Chen Y, Lu Y, Pei C, Liang J, Ding P, Chen S, Hou SZ. Monotropein alleviates secondary liver injury in chronic colitis by regulating TLR4/NF-κB signaling and NLRP3 inflammasome. Eur J Pharmacol 2020;883:173358. [PMID: 32710952 DOI: 10.1016/j.ejphar.2020.173358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]